Etzer Darout is ranked #1180 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Etzer Darout (Barclays) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Etzer Darout's stock ratings?

About 63% of Etzer's ratings were profitable over a one-year hold, with an average return of +5.0% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Etzer Darout

BARC

Etzer Darout

Barclays

Wall Street Analyst

★★★☆☆

#1180

on 13Foresight · ranked by our own returns

63%

Success Rate

+4.6%

Average Return

44 of 70 calls profitable · -0.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 63% of Etzer Darout's ratings turned a profit when each position was held for 1 year — averaging +4.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

202 Buy 26 Hold 15 Sell

Etzer's Stock Coverage 48 ratings · 2026-07-15

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
EXEL Exelixis	Jul 14, 2026	HOLD	Buy -23.6% avg upside 33 analysts	$49.00 12.31% Downside	-0.3%
LEGN Legend Biotech	Jul 14, 2026	BUY	Strong Buy +153.9% avg upside 27 analysts	$80.00 210.66% Upside	-9.3%
ANAB AnaptysBio	Jul 14, 2026	BUY	Strong Buy +12.7% avg upside 26 analysts	$75.00 14.95% Upside	·
PTGX Protagonist Therapeutics	Jul 14, 2026	BUY	Strong Buy -29.1% avg upside 19 analysts	$151.00 16.15% Upside	+5.2%
ONC BeOne Medicines	Jul 14, 2026	BUY	Strong Buy +15.1% avg upside 28 analysts	$403.00 31.18% Upside	·
JAZZ Jazz Pharmaceuticals	Jul 14, 2026	BUY	Strong Buy -7.0% avg upside 35 analysts	$260.00 9.46% Upside	+0.5%
INCY Incyte	Jul 14, 2026	BUY	Buy -12.0% avg upside 47 analysts	$134.00 16.59% Upside	·
TRAX First Tracks Biotherapeutics Inc	Jul 10, 2026	BUY	Strong Buy +12.8% avg upside 7 analysts	$40.00 11.35% Upside	·
TVRD Tvardi Therapeutics	Jul 08, 2026	SELL	Strong Buy +484.5% avg upside 23 analysts	$3.00 4.06% Downside	-0.0%
ABVX Abivax SA Sponsored ADR	Jun 30, 2026	BUY	Strong Buy -3.1% avg upside 15 analysts	$148.00 9.19% Upside	+1.2%
MNPR Monopar Therapeutics Inc	Jun 29, 2026	BUY	Strong Buy -2.8% avg upside 18 analysts	$125.00 17.33% Upside	·
CCCC C4 Therapeutics	Jun 22, 2026	BUY	Strong Buy +364.0% avg upside 19 analysts	$7.00 80.43% Upside	-6.4%
SRRK Scholar Rock Holding	Jun 18, 2026	BUY	Strong Buy +5.3% avg upside 23 analysts	$55.00 2.09% Upside	+19.8%
XNCR Xencor	Jun 16, 2026	BUY	Strong Buy +119.7% avg upside 27 analysts	$27.00 81.62% Upside	·
NUVL Nuvalent	Jun 09, 2026	HOLD	Buy -0.7% avg upside 21 analysts	$124.00 0.08% Upside	+0.5%
KURA Kura Oncology	Jun 04, 2026	BUY	Strong Buy +132.2% avg upside 26 analysts	$28.00 146.56% Upside	+28.2%
ARVN Arvinas Holding Company	Jun 03, 2026	BUY	Strong Buy +239.4% avg upside 27 analysts	$20.00 140.04% Upside	+7.4%
IOVA Iovance Biotherapeutics	Jun 02, 2026	BUY	Strong Buy +221.8% avg upside 24 analysts	$11.00 174.05% Upside	+3.2%
SMMT Summit Therapeutics	Jun 02, 2026	HOLD	Strong Buy +89.9% avg upside 27 analysts	$18.00 16.02% Upside	+2.6%
VIR Vir Biotechnology	Jun 01, 2026	BUY	Strong Buy +173.8% avg upside 16 analysts	$30.00 212.40% Upside	+10.3%
RLAY Relay Therapeutics	May 20, 2026	BUY	Strong Buy +5.3% avg upside 19 analysts	$27.00 42.52% Upside	+46.5%
CRVS Corvus Pharmaceuticals	May 15, 2026	BUY	Strong Buy +71.1% avg upside 14 analysts	$28.00 87.09% Upside	+30.6%
ORKA Oruka Therapeutics	May 13, 2026	BUY	Strong Buy +37.2% avg upside 16 analysts	$160.00 83.90% Upside	+37.4%
MGNX MacroGenics	May 13, 2026	BUY	Buy +304.7% avg upside 25 analysts	$6.00 34.77% Upside	+25.5%
CLDX Celldex	May 08, 2026	BUY	Strong Buy +2.1% avg upside 28 analysts	$48.00 23.45% Upside	+13.1%
JANX Janux Therapeutics Inc	May 08, 2026	SELL	Strong Buy +183.4% avg upside 21 analysts	$14.00 12.38% Downside	-12.0%
CTMX CytomX Therapeutics	May 08, 2026	BUY	Strong Buy +195.5% avg upside 21 analysts	$16.00 326.66% Upside	-4.9%
SNDX Syndax Pharmaceuticals	May 01, 2026	BUY	Strong Buy +50.4% avg upside 27 analysts	$37.00 54.73% Upside	+24.6%
KYMR Kymera Therapeutics	Dec 08, 2025	BUY	Strong Buy -9.4% avg upside 36 analysts	$119.00 5.10% Upside	+26.6%
IVA Inventiva	Apr 04, 2025	BUY	Strong Buy +264.5% avg upside 16 analysts	$9.00 101.48% Upside	+78.2%
BNTX BioNTech SE	Mar 11, 2025	BUY	Strong Buy +51.1% avg upside 26 analysts	$143.00 57.43% Upside	-7.7%
QTTB Q32 Bio	Mar 04, 2025	HOLD	Buy +184.6% avg upside 24 analysts	—	+119.0%
ACRV Acrivon Therapeutics, Inc.	Mar 04, 2025	HOLD	Strong Buy +576.4% avg upside 13 analysts	—	-68.5%
FHTX Foghorn Therapeutics	Mar 04, 2025	HOLD	Strong Buy +120.1% avg upside 17 analysts	—	+29.2%
NRIX Nurix Therapeutics	Mar 04, 2025	HOLD	Strong Buy +37.1% avg upside 28 analysts	—	+14.0%
GMAB Genmab	Mar 04, 2025	HOLD	Strong Buy +22.1% avg upside 26 analysts	—	+20.8%
FATE Fate Therapeutics	Mar 04, 2025	HOLD	Strong Buy +288.2% avg upside 31 analysts	—	+52.6%
NVS Novartis	Mar 04, 2025	HOLD	Buy -10.1% avg upside 24 analysts	—	+53.7%
JSPR Jasper Therapeutics	Feb 27, 2025	BUY	Buy +4302.8% avg upside 17 analysts	$63.00 9062.22% Upside	-75.7%
GB:0MGB Genmab A/S	Aug 11, 2022	HOLD	Buy +15.2% avg upside 22 analysts	$2612.00 38.70% Upside	·
MIRM Mirum Pharmaceuticals	Sep 13, 2021	BUY	Strong Buy -2.9% avg upside 21 analysts	$37.00 69.53% Downside	+26.7%
NTBLQ Notable Labs	May 18, 2021	BUY	Buy +809999900.0% avg upside 12 analysts	$7.00 699999900.01% Upside	·
TRAW Traws Pharma	May 18, 2021	BUY	Buy +4353.8% avg upside 10 analysts	$60.00 8350.72% Upside	-93.1%
DMAC Diamedica Therapeutics	Mar 17, 2021	BUY	Strong Buy +99.4% avg upside 12 analysts	$25.00 227.39% Upside	-74.0%
TARA Protara Therapeutics	Mar 11, 2021	BUY	Strong Buy +1163.8% avg upside 21 analysts	$48.00 1059.46% Upside	-74.9%
FR:IVA Inventiva	Mar 05, 2021	BUY	Strong Buy +367.1% avg upside 5 analysts	$26.32 589.15% Upside	·
ALNY Alnylam Pharma	Feb 22, 2021	HOLD	Strong Buy +22.4% avg upside 51 analysts	$162.00 42.84% Downside	-0.9%
ZYME Zymeworks	Jul 14, 2020	BUY	Strong Buy +29.2% avg upside 25 analysts	$48.00 92.45% Upside	+12.9%

🔒 43 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Etzer Darout — Frequently Asked Questions

How accurate are Etzer Darout's stock ratings?

Based on the calls 13Foresight could measure, about 63% of Etzer's ratings were profitable over a one-year hold, with an average return of +5.0% per rating, or -0.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Etzer ranked on 13Foresight?

Etzer Darout is currently ranked #1180 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Etzer cover?

Etzer most recently has ratings on EXEL, LEGN, ANAB, PTGX, ONC, JAZZ, INCY, TRAX, TVRD, ABVX, MNPR, CCCC and 36 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!